SNY Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of 17.65% compared to Sanofi SA's net margin of 0.33%. Sanofi SA's return on equity of 8.47% beat Blueprint Medicines's return on equity of -49.13%.

Sanofi SA has a consensus price target of $64.10, signalling upside risk potential of 29.74%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.06%. Given that Sanofi SA has higher upside potential than Blueprint Medicines, analysts believe Sanofi SA is more attractive than Blueprint Medicines.

Sanofi SA has a beta of 0.503, which suggesting that the stock is 49.662% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.841, suggesting its less volatile than the S&P 500 by 15.895%.

Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.44%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Blueprint Medicines quarterly revenues of $149.4M. Sanofi SA's net income of $2B is higher than Blueprint Medicines's net income of $496K. Notably, Sanofi SA's price-to-earnings ratio is 17.62x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.54x versus 14.62x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of 17.65% compared to Sanofi SA's net margin of --. Sanofi SA's return on equity of 8.47% beat Innate Pharma SA's return on equity of -72.79%.

Sanofi SA has a consensus price target of $64.10, signalling upside risk potential of 29.74%. On the other hand Innate Pharma SA has an analysts' consensus of $7.86 which suggests that it could grow by 320.14%. Given that Innate Pharma SA has higher upside potential than Sanofi SA, analysts believe Innate Pharma SA is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.503, which suggesting that the stock is 49.662% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.227, suggesting its less volatile than the S&P 500 by 77.33%.

Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.44%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Innate Pharma SA quarterly revenues of --. Sanofi SA's net income of $2B is higher than Innate Pharma SA's net income of --. Notably, Sanofi SA's price-to-earnings ratio is 17.62x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.54x versus 11.19x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Novavax has a net margin of 17.65% compared to Sanofi SA's net margin of 82.81%. Sanofi SA's return on equity of 8.47% beat Novavax's return on equity of --.

Sanofi SA has a consensus price target of $64.10, signalling upside risk potential of 29.74%. On the other hand Novavax has an analysts' consensus of $14.67 which suggests that it could grow by 108.63%. Given that Novavax has higher upside potential than Sanofi SA, analysts believe Novavax is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.503, which suggesting that the stock is 49.662% less volatile than S&P 500. In comparison Novavax has a beta of 2.803, suggesting its more volatile than the S&P 500 by 180.302%.

Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.44%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Novavax quarterly revenues of $626.3M. Sanofi SA's net income of $2B is higher than Novavax's net income of $518.6M. Notably, Sanofi SA's price-to-earnings ratio is 17.62x while Novavax's PE ratio is 2.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.54x versus 0.96x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 17.65% compared to Sanofi SA's net margin of 26.7%. Sanofi SA's return on equity of 8.47% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Sanofi SA has a consensus price target of $64.10, signalling upside risk potential of 29.74%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 39.13%. Given that Regeneron Pharmaceuticals has higher upside potential than Sanofi SA, analysts believe Regeneron Pharmaceuticals is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.503, which suggesting that the stock is 49.662% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Sanofi SA has a quarterly dividend of $2.20 per share corresponding to a yield of 4.44%. Regeneron Pharmaceuticals offers a yield of 0.34% to investors and pays a quarterly dividend of $0.88 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Sanofi SA's net income of $2B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Sanofi SA's price-to-earnings ratio is 17.62x while Regeneron Pharmaceuticals's PE ratio is 13.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.54x versus 4.23x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.